MEDIA ADVISORY --- BIO 2001: Highlight of Events for Tuesday, June 26
| 7 - 8:00 a.m. Plenary Breakfast Ballroom 6 |
Vernon Ellis, International
Chairman and Managing Partner, Accenture, CEO/COO of International Pharmaceutical
Company Michael Jackson, Global Discovery, Johnson & Johnson Bill Rastetter, Chief Executive Officer, IDEC
|
| 8:15 - 9:45 a.m. Finance Track Session Upper Level, Room 11 |
Sell-Side Analysts: A 2001
Roundup, this annual BIO panel will be chaired by Ray Dittamore, Managing
Partner, Ernst & Young LLP, and will feature a number of well-known biotech
analysts who will share their views on where the industry has been and where
it's going.
|
| 8:15 - 9:45 a.m. Clinical/Regulatory Upper Level, Room 1B |
Developing AIDS Drugs for
the New Millennium, chaired by David W. Barry M.D., Chairman and CEO,
Triangle Pharmaceuticals, Inc., this session discusses how companies can
navigate regulation and competition to produce and market new drugs to fight
HIV.
|
| 8:15 - 9:45 a.m. Upper Level, Room 10 Upper Level, Room 11 |
Apoptosis-Based Therapies,
recent insights into cell death mechanisms are revealing strategies for
development of new pharmaceuticals and other types of therapeutic strategies
for combating defective apoptosis regulation during disease.
|
| 8:15 - 9:45 a.m. Sales/Marketing Session Mezzanine Level, Room 14B |
How will the Biotechnology
Revolution Affect the Current U.S. Health Care Supply System, Marsha
K. Millonig, MBA, R.Ph., Vice President, Health Care Distribution Management
Association Health Care Foundation will chair a discussion of whether 98
pipeline entities studied by HDMA will enhance, replace or compete with
products already on the market and how they will affect the health care
system.
|
| 8:15 - 9:45 a.m. Science Track Session Upper Level, Room 9 |
Converting the Human Genome
into Therapeutics: from Genes to Drugs, a panel chaired by Dr. Stan
Watson, MHIR University of Michigan, will discuss strategies to accelerate
the drug development process now that the sequencing of the human genome
has provided thousands of new but unvalidated targets.
|
| 8:15 - 11:45 a.m. Food and Ag Track Session Upper Level, Room 2 |
Safety and Regulatory Oversight
of Novel Crops Symposium: A Public Discussion, chaired by Terry Medley,
Vice President, Global Regulatory Affairs, DuPont Biosolutions Enterprise,
U.S. government representatives will present their views on the comprehensive
nature of their oversight, communication with the public and mechanisms
for public input to their decision-making.
|
| 9:30 a.m. Press Conference Upper Level, Room 5B |
Viaken Systems Press Briefing,
Viaken Systems closes $13 million in second round financing. Sterling Venture
Partners leads round, including Allianz, MacAndrews & Forbes and returning
investors, Core Capital and Mid-Atlantic Venture Funds.
|
| 10 a.m. Press Conference Upper Level, Room 5B |
Question and Answer Session
with Dr. Walter Seufert, President, Envir Safety and Energy Division,
BASF. (This session immediately follows Dr. Seufert.'s symposium on Convention
Manufacturing and Chemical Waster Generation Can the Marriage of Chemistry
and Biotechnology Bring Solutions? which is held in Upper Level Room
3.
|
| 10:15 - 11:45 a.m. Clinical Regulatory Track Upper Level, Room 1B |
Bringing Genetic Medicine
into the Mainstream, Presentations will bring participants up-to-date
on attempts to define analytic and clinic validity for testing of mutations
in several model genes; the steps needed to ensure that evolving technologies
receive proper attention by the organizations that establish billing codes,
fees and reimbursement; and patenting, licensing and regulation of new technologies.
The activities of the U.S. Department of Health and Human Services Secretary's
Advisory Committee on Genetic Testing (SACGT) will also be reported in this
session chaired by Edward R.B. McCabe, M.D., Ph.D., Chair, Department of
Pediatrics, UCLA, and Chair, SACGT, UCLA School of Medicine.
|
| 10:15 - 11:45 a.m. Science Track Session Upper Level, Room 10 |
Biotechnology at the National
Laboratories, Co-chairs Reinhold Mann, Life Sciences Division Director,
Oak Ridge National Laboratory and F. Blaine Metting, Ph.D., Fundamental
Sciences Division, Pacific Northwest National Laboratory will provide an
overview of biotechnology research at the U.S. Department of Energy national
laboratories.
|
|
12 - 1:45 p.m. |
Dr. Florence Wambugu, Director, ISSA AfriCenter, Kenya Cameron Marley, patient
|
|
2 - 3:00 p.m. |
Planting the Future Through
Space, C. Blake Power, Director of Outreach, NASA Space Product Development
Program, chairs a panel on how companies are using space and microgravity
in their food and agriculture-related research.
|
|
2 - 3:30 p.m. |
Optimizing Genes and Proteins
with Directed Evolution Technologies, this panel will discuss the field
of directed evolution as it applies to human therapeutics, agriculture and
industrial enzymes.
|
|
2 - 3:30 p.m. |
The Future of DNA Microarrays
and Bioinformatics in Research and Diagnostics, chaired by August Sick,
Senior Manager, Business Development, Invitrogen Corporation, this session
will present recent applications demonstrating the power of microarrays
and advanced bioinformatics technologies in identifying differentially expressed
biomarker genes.
|
|
2 - 3:30 p.m. |
Oversight of Gene Therapy:
Protecting Patients and Promoting Research The FDA and NIH have recently formally issued plans that would dramatically change the regulatory environment for companies doing gene therapy experiments. This program, chaired by Michael J. Werner, Esq., Director, Federal Government Relations/Bioethics Counsel, Biotechnology Industry Organization, will discuss several important issues surrounding regulation in the industry.
|
|
2 - 5:30 p.m. |
Mergers & Acquisitions
Symposium, chaired by Richard A. Leavitt, Principal, William Gallagher
Associates Insurance Brokers, Inc., and Stephen Ferruolo, Shareholder, Heller
Ehrman White & McAuliffe LLP, speakers on this panel will address the
future of genomics and the information challenge it poses.
|
|
3 p.m. |
Florence Wambugu, Ph.D.,
Director, ISSA AfriCenter, Kenya, will discuss her book, "Modifying
Africa: How Biotechnology Can Benfit the Poor and Hungry: A Case Study from
Kenya."
|
|
4 p.m. |
MediChem/Neurocrine Announcement,
MediChem (NASDAQ:MCLS) a Chicago-based drug discovery technology and services
company, and Neurocrine Biosciences (NASDAQ: NBIX), a San Diego-based biopharmaceutical
discovery and development company, will announce that they have entered
into a two-year collaborative GPCR agreement in proteomics for new drug
development.
|
|
4 - 5:30 p.m. |
Animal, Mineral or Vegetable:
Which Model for Product Discovery, John A. Ryals, Ph.D., President and
CEO, Paradigm Genetics, chairs a discussion about the utility of different
gene-based discovery models that have influenced the success of the genomics
industry.
|
|
4 - 5:30 p.m. |
The Impact of State Drug
Price Control Schemes on Emerging Biotech Companies, Thomas C. Norton,
Senior Vice President, SPECTRUM Science Public Relations, chairs a discussion
of the consequences of state drug price control programs.
|
|
4 - 5:30 p.m. |
Managing Diabetes: Advances
in Insulin Therapy from Novel Delivery Systems, Lars Karlsen, Senior
Vice President, Head of Project Portfolio Managements, Novo Nordisk A/S,
chairs a discussion of how recent advances in insulin delivery will improve
patient compliance with insulin regimens and quality of life.
|
|
4 - 5:30 p.m. |
Raiders of the Lost Genome:
Gene Analysis on the Post-Genome Era, chaired by Teresa W. Ayers, CEO
and Director, Genomica, this panel will review and discuss a variety of
new technologies that will facilitate the deciphering of genetic data and
provide gene function information for product development.
|
|
4 - 5:30 p.m. |
Accepting New Technology:
Media and Public Perception of Risks and Benefits, Linda Thrane, Executive
Director, Council for Biotechnology Information, and other experts from
the fields of risk communication, consumer research and the media will provide
insight and guidance.
|